Ladies and gentlemen, welcome to BWX Technologies Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the company’s prepared remarks we will conduct a question-and-answer session and instructions will be given at that time. I would now like to turn the call over to our host, Chase Jacobson with BWXT's Vice President of Investor Relations. Please go ahead.

Thank you, Sheryl. Good evening and welcome to today's call. Joining me are Rex Geveden, President and CEO; and Robb LeMasters, Senior Vice President and CFO. On today’s call, we will reference the third quarter 2023 earnings presentation that is available on the Investors section of the BWXT website. We will also discuss certain matters that constitute forward-looking statements. These statements involve risks and uncertainties, including those described in the safe harbor provision found in the investor materials and the company's SEC filings. We will frequently discuss non-GAAP financial measures, which are reconciled to GAAP measures in the appendix of the earnings presentation that can be found on the Investors section of the BWXT website. I would now like to turn the call over to Rex.

Thank you, Chase, and good evening to everyone. This afternoon we reported solid third quarter results that were slightly ahead of our expectations. The quarter was highlighted by a robust 13% organic revenue growth with double-digit revenue growth in both segments. Adjusted EBITDA grew 6% compared to the same quarter last year as higher revenue and government operations, and solid revenue and margin performance in commercial operations were offset by lower margin in our government operations segment and some growth in corporate expense. As we forecasted last quarter, although higher sequentially government operations margins were somewhat compressed by the onboarding of new team members and less favorable product mix, while commercial operations margins benefited from operational improvements and medical profitability. Adjusted earnings per share declined 3% to $0.67 as higher EBITDA was offset by non-operating items. Overall and consistent with what we have experienced throughout 2023, the combination of steady advancements in our core franchises and incremental increases from new growth vectors is producing strong organic top line growth even in these challenging and unpredictable economic times. Coupled with our focus on operational excellence and functional continuous improvement, we expect to produce good financial performance and strong cash flow throughout the remainder of 2023 and 2024. Based on our year-to-date performance and our expectations for the fourth quarter, we are narrowing our 2023 adjusted earnings per share guidance to $2.90 to $2.95, the midpoint of which is slightly higher than where we started the year. Our guidance assumes approximately 8% year-over-year adjusted EBITDA growth. And as Rob will detail in his remarks, we are pleased to have a similarly positive outlook for 2024, anchored again by solid organic growth at the top and bottom line. Our preliminary view is that we can grow revenue, EBITDA, and earnings at a mid-single-digit rate in 2024 and continue to drive improved free cash flow. Last quarter I provided a detailed update on some of the major secular themes driving our demand outlook including the impacts of the great power competition and decarbonization of the grid. As we begin to turn the page on 2023, I expect these same themes to remain key drivers of the increased application of nuclear solutions in our key national security, clean energy, and nuclear medicine end markets. Looking through that lens, let's step through the drivers of our segment results including key wins in each segment. Starting with the government operations segment. We had a strong third quarter with 13% organic revenue growth driven by an increase in naval propulsion volume and strong growth in nuclear fuel services and micro reactors. On the demand outlook, our naval propulsion business prospects remain robust. Underpinned by the 30-year shipbuilding plan, which supports the government strategy to bulk up our strategic force capabilities, including a recapitalization of the US Navy nuclear fleet on top of a consistent procurement of Virginia-class submarines. The current shipbuilding plan calls for 10 years of serial procurement of Columbia class submarines beginning in 2026 and the potential for the Ford-class aircraft carrier to move to four-year ordering centers beginning in 2028. We are also anticipating incremental demand for submarines resulting from the AUKUS trilateral security agreement signed a little more than one year ago. To that end, Australia's recent announcement to invest $3 billion into the US naval manufacturing industrial base is a positive step in helping to increase US submarine production not only to meet our country's needs, but also to support incremental demand from our key allies including Australia and the United Kingdom. However, even as AUKUS efforts mature, our primary focus continues to be fully supporting naval reactors. Just last week we announced a $300 million award for the manufacturing of naval nuclear fuel through mid-2025. We expect to finalize the other elements of our next multiyear pricing agreement including reactors and key components of the propulsion package in the coming months. Within our non-naval propulsion government business, which now comprises about 20% of the segment's total revenue up from about 15% just two years ago, we're also seeing nice growth in emerging opportunities. Leading this growth, of course, are our microreactor programs within the Advanced Technologies division of the segment. During the third quarter, we booked the initial portion of our $200 million contract for the DRACO project, the first demonstration of a nuclear thermal rocket engine in space. BWXT will manufacture the reactor's hardware and complex fuel and assemble the reactor in our Lynchburg facility before delivering the fully fueled subsystem for spacecraft integration. Programs like DRACO and Pele are progressing well and others that we are pursuing show how our investments in talent and infrastructure are driving growth beyond our core, enabling BWXT to offer the US government breakthrough nuclear solutions for applications in all national security domains including sea, land, and space. Our wins with government customers are also creating opportunities to develop microreactors for novel commercial applications. While some of our nuclear technology peers are taking more significant and open-ended profit risk to enter these nascent markets, BWXT is taking a page out of the Navy's history books. As some of you will know, early naval investments in the 1950s led directly to the first commercial nuclear power reactor in Shippingport, Pennsylvania. We believe this model is still sensible today as we can leverage government program funding and experience to advance novel commercial nuclear concepts while investing modest amounts of capital to further develop nuclear solutions for maritime, remote power, or other industrial applications. In that vein, we recently announced early-stage contracts with the Wyoming Energy Authority stemming from our involvement in the advanced reactor development program to assess the potential for microreactors at mining sites in the state. We also announced a relationship with Crowley to explore the use of a microreactor on a barge that could be used for backup emergency power. Another part of the government operations segment that is sometimes overlooked is our special materials business. While most of our investors are aware of the strength of our nuclear fuel services franchise, over the past several years we have methodically assembled a broader field based on our strengths and technical capabilities in radiochemical processing and special materials handling and accountability. Given the reduction of Cold War-era infrastructure and other capacity constraints within the government laboratory complex, BWXT has worked with its government customers to pilot and scale back up production systems for special nuclear materials. The special materials franchise includes uranium downblending, where we have converted highly enriched stockpile material into lower enriched material under a current contract since 2018. The TRISO coated fuel line we stood up in 2021 and the uranium metal processing line at our nuclear fuel facility that began production last year. The objective of which is to return valuable national security material to the stockpile for later use in naval fuels or other national security applications. We further expanded this unique line of business in late August by securing an MSA contract to recycle scrap material from the Y-12 National Security Complex into high assay, low-enriched uranium or HALEU feedstock material. This material is an important stopgap source for much-needed HALEU for the DOE's advanced reactor development program that requires higher assay nuclear fuels to support prototype development. We are in regular discussions with the Department of Energy, the National Nuclear Security Administration, and other government agencies about where BWXT can be of assistance in supporting their missions, so more to come on this special materials processing platform, as it blossoms into a larger business line within the government operations segment. Looking ahead to 2024, we believe these demand trends will continue to support growth in our government operations segment. However, as we laid out at our November 2021 Investor Day, the law and the ordering cadence for the Ford-class aircraft carrier in 2024 and 2025 creates some headwinds that we expect to overcome in the next two years. Turning to commercial operations. Revenue in this segment grew 10%, with high single-digit growth in commercial nuclear and another quarter of robust double-digit growth in medical. Backlog in the segment, which is almost entirely related to our commercial nuclear business lines, was up sequentially for a third consecutive quarter and is up 14% over last year. This highlights the robust demand we are seeing in the market, which will continue for the next several years, given demand for nuclear power in Canada and around the world. As we discussed in more detail last quarter, the Ontario government is seeking to double the scale of the power grid by 2050 to meet projected demand and is fully committed to using nuclear to satisfy a large portion of this demand. This is evidenced by three recent developments including Ontario Power Generation's commitment to build four BWRX-300 small modular reactors at the Darlington site, life extensions of existing plants at the Pickering site, and the potential for new large-scale power reactors at the Bruce Power Nuclear Generating Station, among many others. We see international momentum as well. We have talked about the potential for new nuclear in Europe in countries like the UK, Poland, and Romania, as they seek to add clean baseload power and to improve their energy security postures. Just in September, Canada announced export financing of CAD3 billion to be used for the construction of two CANDU reactors at the Cernavoda Nuclear Power Station in Romania. Our strong position as a fuel and equipment provider in the CANDU reactor market and our role as a merchant supplier of large critical equipment to the SMR markets positions us well to benefit from such projects in the global market. At BWXT Medical, revenue growth in our base diagnostic and contract drug manufacturing businesses continues to accelerate, growing approximately 30% in the quarter. We expect this trend to continue as demand for isotopes such as tritium and germanium using cardiac and cancer imaging studies remain strong, while we experienced the rising tide of demand for newer therapeutic isotopes like lutetium and actinium. It is worth noting that our proprietary actinium generators are now being used exclusively by Bayer for late-stage human clinical trials in Europe. As it relates to our tech 99 product development, our team is diligently working to respond to the questions and data requests that we received from the FDA this summer. We have conducted several successful test runs of tech 99 generator production with radiated material using the target delivery system at the OPG Darlington site and we continue to work towards commercialization of the product next year. Overall, our Commercial Operations segment is poised for continued solid growth in 2024 with improving profitability, based upon a better mix in commercial nuclear and higher profitability in medical. I would also like to take a moment to discuss a few of the initiatives we have in place to sharpen our business execution and improve the day-to-day operational functionality of our company. Last quarter, I discussed that on top of the significant financial capital we invested in the business over the last several years, we've also made significant investments in human capital throughout the organization to ensure we have the people, systems, and processes to skillfully manage the strong growth we see ahead. Not only are we focused on capturing growth, but we are also intent on honing our business through the use of AI and automation throughout the organization, implementing more efficient operational effectiveness practices including real-time monitoring and reporting on large machine tool utilization at all our major US plants and enhanced human resources and financial back-office platforms to increase the efficiency of administrative functions. We expect these initiatives to maintain our strong competitiveness in the markets we serve and to drive returns on capital by sustaining our industry-leading growth, solid margin performance, and robust free cash flow generation. In conclusion, as we look at our portfolio and our dual focus on growth and execution, I couldn't be more confident in our employees and how they are positioning BWXT to serve the nuclear markets around our three key capabilities: manufacturing, processing, and services mainly in power and propulsion applications. The core of BWXT is our significant experience in manufacturing critical nuclear systems and components, handling and processing highly complex materials, and providing services around these capabilities. Because of our extensive experience in the nuclear markets, unmatched facilities in the US, Canada, and the UK and our deep technical expertise, we are uniquely positioned to benefit from the trends driving our markets. We are focused on taking these power and propulsion solutions to meet the demands of our distinguished customers in the national security, clean energy, and nuclear medicine markets. Before I turn the call over to Rob to discuss the third quarter financial results in more detail and to discuss our updated 2023 guidance and preliminary 2024 outlook, I would like to take a moment to express my gratitude to the men and women at BWXT for their hard work and dedication in supporting the many critical missions carried out by the customers we serve. It is widely known that the US has deployed two carrier strike groups to the Middle East to support Israel led by the USS Ford and the USS Eisenhower aircraft carriers, both of which are powered by BWXT reactors. This is a stark reminder of the importance of the work we do every day at BWXT in supporting the US and our most important allies. With that, I will turn the call over to Rob.

Thanks, Rex, and good evening, everyone. I'll start with some total company financial highlights on slide four of the earnings presentation. Third quarter revenue was $590 million, up 13% organically on a consolidated basis with double-digit growth in both government and commercial operations. Adjusted EBITDA was $107 million, up 6% year-over-year as higher revenue was complemented by improved margins in commercial operations, but partially offset by lower margins in government operations and higher corporate EBITDA spend driven by some seasonally stronger healthcare costs. We still see this corporate EBITDA line coming in at the upper end of the $10 million to $15 million range with fourth quarter coming in more like the level we saw in the second quarter this year. Looking into 2024, we expect corporate EBITDA expense to flatten out in the mid-teens range and only grow at inflationary rates thereafter. I will note that despite seasonally lower revenue and the higher corporate expense, adjusted EBITDA was essentially flat compared to the second quarter of 2023, reflecting solid underlying performance in our government business, better margins in commercial power, and improved profitability in medical. Adjusted earnings per share was $0.67 compared to $0.69 in the prior year quarter. As you can see in the EPS bridge on slide five, as has been the case throughout the year, the year-over-year decline was due to non-operational items including lower pension income and higher interest expense. Our adjusted effective tax rate was 22.6% in the quarter, mainly due to the adjustment of certain stock compensation expenses that had a disproportionate impact on the quarter. Nonetheless, we still expect a full year tax rate of approximately 24%, meaning the fourth quarter rate will likely be a tad higher than the full year rate. Despite modestly lower net income, free cash flow improved to $43 million compared to $25 million in the third quarter of 2022, driven by improved working capital management and lower capital expenditures. CapEx was roughly $31 million in the quarter and consisted of maintenance CapEx and select growth initiatives, including investments for our Pele and DRACO microreactor programs. Moving now to the segment results on slide six. In government operations, third quarter revenue was up 13% to $478 million, driven by higher naval nuclear component production and microreactor volume though partially offset by lower long lead material procurement. Third quarter adjusted EBITDA in the segment was $99 million, up 10% from last year as higher revenue was offset by less favorable mix and inefficiencies related to new hiring as we continue to expand the size of our workforce to meet growing demand. EBITDA margin in the segment was 20.7%, down compared to last year but up from 19.4% in the second quarter. This sequential increase was driven by better utilization and onboarding processes, as well as nuclear manufacturing improvements. We are tracking well to having one of the best years of gross hiring in our history, while also stemming the negative attrition trend we had seen in the wake of COVID. Going forward, we expect continued solid performance in government operations, with some lingering effects from onboarding timing of projects as well as mix, which will enable us to hold our underlying margins in this segment relatively steady in 2024. In commercial operations, revenue was up 10% and driven by increases in component manufacturing and field service activity in our commercial nuclear business as well as robust BWXT Medical revenue growth, and partially offset by lower fuel handling volume. Year-to-date reported commercial operations revenue is up approximately 7% despite a 5% currency headwind due to the appreciation of the U.S. dollar versus the Canadian dollar highlighting the underlying strength of our commercial nuclear and medical business. Second quarter commercial operations adjusted EBITDA was up approximately $2.5 million to $14 million, driven largely by improved profitability in medical. Similar to the trends we have experienced throughout the year, this was partially offset by the impact of less favorable mix in commercial nuclear that was skewed toward field service refurbishment activity and less outage work compared to last year. We expect this mix to remain relatively constant in 2024. Turning now to guidance for the remainder of 2023 and a preliminary outlook for 2024 on slide seven. We are narrowing our 2023 adjusted EPS guidance to $2.90 and to $2.95, the midpoint of which is in line with our previous guidance and slightly above where we started the year. We are maintaining our operating assumptions for revenue to be up high single digits from more than $2.4 billion, with both government operations and commercial operations near the higher end of our forecasted high single-digit growth and mid-single-digit growth guidance respectively. Overall, we expect EBITDA margins of approximately 20%, leading to adjusted EBITDA of approximately $475 million up high single digits compared to 2022 driven almost entirely by organic growth. Our full-year guidance implies fourth quarter consolidated EBITDA margin to be higher than the third quarter driven by improved medical profitability and better commercial nuclear mix, as well as slightly improving underlying government performance plus the potential to recognize a recovery on nonnuclear components. Turning now to our preliminary outlook for 2024. Overall, we expect to see another year of good operational performance with mid-single-digit growth in revenue, adjusted EBITDA, and EPS, and continued strong free cash flow. In government operations, we expect modest revenue growth as contributions from our non-naval programs, including new microreactor projects such as DRACO and the expanded special materials franchise that Rex walked through earlier, to be partially offset by the adverse impact of the shipbuilding ordering keys. As we have communicated, the lull in our aircraft carrier-related work in 2024 and 2025 will only be partially offset by growth in Columbia class submarines. Government EBITDA margins are likely to be modestly lower compared to 2023 as solid underlying performance will be offset by the impact of revenue mix, particularly as it relates to our cost-reimbursable microreactor projects and the non-recurring recovery benefit we expect in the fourth quarter of 2023. Excluding this benefit, government operations should be relatively flat compared to 2023. In commercial operations, we expect continued strong growth driven by both commercial nuclear and medical, given favorable market trends and the opportunities that Rex discussed in his remarks. With this growth, we expect improved EBITDA margin from steady performance in commercial nuclear and improving contributions from BWXT Medical. Lastly, our capital expenditure targets continue to be focused on disciplined maintenance CapEx spending plus incremental CapEx to support growing demand for micro reactors, commercial nuclear, and therapeutics. At this point in time, we expect CapEx to remain in line with 2023. Additionally, we remain focused on working capital efficiency throughout the organization and in how we contract with our customers and suppliers. In total, we expect these factors to produce another strong year of free cash flow, with investors seeing free cash flow growing faster than our mid-single-digit EBITDA growth. To sum it up, we have had another solid quarter and are well-positioned for continued growth in 2024. Demand trends in our business remain strong, and while we are not immune to global macroeconomic factors, the high priority of our government programs and the underlying secular themes driving our business leave us relatively insulated from changes in government funding patterns and other macro risks. As Rex discussed, we are committed to capturing growth and are taking the initiative to drive more predictable earnings and free cash flow conversion, which combined with our unique assets and technical capabilities will continue to differentiate BWXT and its peers. And with that, we look forward to taking your questions.

Our first question comes from Peter Arment with Baird. Your line is now open.

Rex, it sounds like you've done a great job on all the hiring and at least from a gross perspective and dealing with some of the attrition. But is that going to linger into next year just thinking about the margins at your government operations?

Yes, thanks, Peter. Good evening. To add some insight into our hiring efforts, I believe we are performing well in talent acquisition. Additionally, we've been successfully reducing employee turnover, which has significantly improved. We're approaching a mid-single-digit attrition rate when excluding retirements and involuntary separations. The combination of these factors is beneficial for our business, Peter. Given our growth rate, we are continuously onboarding, hiring, and training new staff, which does introduce some challenges associated with that growth. I expect this situation will persist for a while. Would you like to add anything, Rob?

Yes. Yes. Just to give you a couple of numbers up on where we stand. Third quarter was excellent. I think last quarter we talked about how we just saw the building momentum month-upon-month. As we look at the third quarter from a hiring standpoint on the sort of growth side, we're up almost 30% versus the levels that we brought in Q2. So, we are still onboarding quite a bit. Rex talked a little bit about the attrition. That number has actually gone back to a sort of more normalized level of mid-single digits. So, we're really seeing good performance there. So, we both want to bring in new employees and we want to retain them longer. And also just the overall onboarding, I think you saw in our margin performance just sequentially, we still have an issue of sort of utilization, but our efficiency has really been quite strong. On a per hour basis, if you will, we're really matching what the customer is asking for. So, it's taking a little bit of a drag on utilization but our efficiency is quite strong. So, I'm pretty proud of that from the team.

I appreciate those details. Regarding your comments on 2024, I think we all expected the situation you outlined concerning government involvement, where the impact from Ford will decrease, and eventually Columbia will start to balance that out. Will we see Columbia play a larger role in 2025? How should we consider that, especially since the schedule significantly increases in the latter half of the decade?

Yes, I think we're doing slightly better than expected. We're making progress in overall shipbuilding, particularly with the carrier program and the Columbia project. We're experiencing strength in our microreactor business within the AC division and also in some specialized materials segments. We've had a significant win with HEU Metal, which is providing a boost for both 2024 and 2025. While it's probably too early to fully project 2025, I hope we can exceed expectations as we did in 2024, where we are now seeing some growth. A year or two ago, you asked me what we anticipated seeing, and I'm glad to provide that update. It's worth noting that the carrier program won't impact us immediately at the start of 2024; rather, it will gradually build up through the year, which means we'll feel the effect more fully in 2025. This is something we need to manage, but I'm confident we'll navigate 2025 effectively.

I appreciate that color, Rob. And then just one last one. On the – Rex, just it sounds like you've had a lot of back and forth with the FDA. It still sounds like you're thinking tracking for commercialization in 2024. Any color on you originally planned on a priority review, what that timeline looks like today when you think about just your exchanges that you've had with the FDA?

Yes, I'd say no change in our outlook there at all, Peter. So we expect to be commercial sometime in 2024. The work that we've done in radiating the material at Darlington was promising, and so no change on the outlook there. It looks good for us.

Peter, as we indicated for 2024, we've always mentioned that the contribution to the tech business will be quite small. We anticipate beginning commercialization, but it will only be at a low scale. Therefore, our guidance does not factor in a full-year ramp of that product or anything similar. We have been cautious in our estimates. We'll see how it progresses.

Appreciate the details. Nice result.

Thanks, Peter.

Your next question comes from the line of Michael Ciarmoli with Truist Securities. You may now go ahead.

Good evening, gentlemen. Great results. Thank you for taking my question. Rob, following up on the topic Peter mentioned, regarding the assumptions for next year with Tc-99. While this isn’t reflected in the full-year guidance, if you proceed with commercialization, could we anticipate a more significant impact on EBITDA margins due to better overhead absorption and actual product sales? I’m trying to understand how that might affect the EBITDA margins next year.

Yeah. I think overall for the commercial division, we do see tailwinds for margin overall for the year. I wouldn't attribute much of that to the tech business because even if we get a small bit right, that's a ramping product line, if you will. So frankly, we're going to kind of bring that in at a lower margin, right? Because we're going to be just testing supply, getting it out there and probably not working super efficiently on kind of the first couple of batches if we even have that kind of in 2024. So I wouldn't say that's a huge driver. I think what is the big driver is just a generally larger bit of the medical revenue. So we've talked about the fact that we just put up another quarter of excellent growth. Last quarter we said it was a little bit above 20%; now we're saying this quarter is 30%. I think as we look at next year we can continue that underlying trend of that base business. And then the way I'm thinking about it is, okay that's the underlying business. And now therapeutics kind of get layered on top of that and maybe a little of tax into 2024 that all should actually accelerate the growth rate from that 30% as we look out to next year.

Okay. I know you recently reached break-even at the EBITDA level in medical. Were you EBITDA positive for the entire quarter?

We were. We do model that business out on a quarterly basis. We're not going to be guiding that. But yes, from this point forward I see that business is making money at the EBITDA level, and then we put out that targets, we still stand by that $200 million and $75 million of EBITDA. So when we look out a couple of years, the line to get there is still staggered, but we'll get.

Got it. Perfect. And then Rex, I got on a few minutes late. I may have missed this. Just on AUKUS and what's been going on with the supplemental support for the industrial base? I mean, I know maybe more over the summer you guys weren't as overly optimistic on that being a big growth driver. But it would seem like if Virginia class is going to get produced and delivered to Australia in 2032, I mean, it would have to start flowing through your facilities pretty early here. I mean what's the latest thinking on kind of AUKUS?

I think the situation is looking a bit more positive than we had previously discussed. Based on the $3 billion investment from Australia into the US submarine industrial sector, along with another $3 billion in supplemental funding from the White House to Congress, it appears that the industrial base and decision-makers are getting ready for increased demand. We're optimistic that this demand will be incremental. The 3% to 5% increase would be added on top of our standard Virginia production, and the industrial base will need to produce approximately 2.3 submarines annually. Additionally, we expect to have involvement with the SSN Augus boat that will be delivered to both the UK and Australia, which will have long-term benefits for us. Overall, this all indicates positive incremental demand, which is certainly favorable for our business.

Got it. Would you need to require any?

Michael, it seems you were asking whether incremental CapEx would be necessary. That depends on the pace of acquisitions. I mentioned earlier that of the $6 billion from both U.S. and Australian appropriation sources, some of it will be allocated to industrial use. We expect to gain some of that. We'll need to determine where the capital will be allocated, but overall, things are looking positive for us.

Your next question comes from the line of Scott Deuschle with Deutsche Bank. Your line is now open.

Hi. Good afternoon.

Hi, Scott.

Hi, Scott.

Robb, it looks like the EACs got a lot better this quarter at least relative to the first half. So maybe you could just talk about if there are any non-recurring elements that drove that or if that was just broad-based performance.

Yes. No, that was in our government segment. In general, we've been grinding through as we've had the sort of labor inefficiencies relative to probably how we sold. We had inflation headwinds. We had, frankly, all of that in the past couple of years. And you're exactly right in the third quarter, we did have better performance so we saw better EACs. I think all the efforts that we have and now that we've sort of gotten better at onboarding, I see the prospects for continued positive EACs going forward.

Okay. Great. And then Robb you talked a bit about this in the prepared remarks there, but maybe you can just level set us on where you're at in the missile tube recovery negotiations? How much you expect to recover in the confidence center you have in getting that here in the fourth quarter?

Yes. I think the communications are quite good. We're obviously negotiating with our customer and they have to interact with the Navy. I think those discussions are quite good. I think we've made a good case. And so we have not actually gotten to a number yet which is why we're trying to guide with all that in mind for the fourth quarter. I think we've talked about in the past that we had a pretty chunky negative item last year. So we're hoping to recover that and then some. So that's the way we're thinking. We're not really at liberty yet because we haven't actually settled on a true number at this point. But the communication is great, and yes, we're looking forward to getting that behind us in the fourth quarter.

Okay. And then last question just an accounting question. The depreciation for the technetium-99 product line does that kick in on a straight-line basis once you get the FDA approval? And if you're slow to ramp up sales then you take the depreciation hit, is there a risk to EBIT margins at commercial operations? Obviously, EBITDA won't be affected. Just trying to think about the EBIT margin impact and what it means for EPS if that treatment gets.

Yes, that's a good question. Generally, it relates to when assets are utilized commercially. It's not solely dependent on FDA approval. There are multiple phases; different assets are activated at different times, such as the target delivery system and those at the facility, so it's not all deployed simultaneously but rather in stages. As we enter the market, our goal is to respond quickly to market demands, which ties into earlier discussions. We won't initially see a complete revenue run rate, and the product won't be immediately highly profitable. It will take a quarter or two to reach profitability. When I mention profitability, I'm referring to EBIT, which accounts for depreciation, a significant fixed cost we'll have to manage. We've anticipated this scenario, especially considering the pace we outlined during Investor Day regarding the D&A challenges we need to overcome to achieve our profitability goals.

Okay. Thank you.

Sure.

Your next question comes from the line of Ron Epstein with Bank of America. Ron, your line is now open.

Hey, good afternoon folks. Just a couple of quick ones. On the last quarter of the year, the way things are lining up it seems like it would be the best quarter ever for the company. What gives you confidence about that? And is there any one single thing that's driving that? Like what can we as outsiders keep an eye on to just get a sense that that's going to play out?

Hey, Ron, it would not be a record quarter based on the midpoint of our guidance. We've achieved similar quarters in the past, with last year's figure at $0.95. Two years ago, it was also $0.95, and last year was 93%. So, it's within the range of what we delivered in the fourth quarter. We adjust the TSG contracts, which is important for a growing business like ours, especially at these rates, as the fourth quarter usually tends to be our strongest. We have reasonable confidence that we can achieve this and a successful track record to back it up.

Got it. Got it. And then just maybe a bigger picture question on just submarine demand a bit large. Are you getting any signals from the Navy of Virginia-class rates moving at all? I mean, there's been supposedly there's been investments in the industrial base. And the Navy keeps talking about we want three Virginia class, and everybody is struggling to get out to right like 1.7, 1.6. Are you seeing any movement upward there? I mean how should we think about Virginia class down the road? I mean will they ever get to 3? Is that just sort of a dreaming number? How should we think about it?

Well, I think the right way to think about it is that the steady-state production rate should settle out at two. And I think that it's fair to say, the constraint there is the shipyards and certainly not our production capacity. We're kind of producing to the shipbuilding schedule at present rates. And so the shipyards have to get to that rate. And if you layer ocean on top of that, people are talking about sort of 2.3 Virginias a year coming out of the shipyards. I don't think there's a production rate of three that's anticipated but blending those Australian ships and getting to 2.3 does seem plausible. And I think, clearly, the investment from Congress and from the Australians is intended to support that. And so it's my expectation that the industrial base will respond appropriately.

What are your thoughts, Rex, on the labor and infrastructure needed for the shipyards to achieve the required production rate? Is that something feasible within a couple of years, and how challenging will it be to reach that goal?

I won't speak for the shipyards, but I can share our own experience. Labor has been difficult to find, and we have really had to put in a lot of effort to secure it. However, I trust in the capital and free markets to organize the supply chain according to demand, so I am optimistic that there will be some self-correction in the coming years.

Yes. Got it. All right. Thank you very much.

Sure.

Your next question comes from Pete Skibitski from Alembic Global. Your line is open, Pete.

Hey, good evening, everyone. It was a solid quarter. I want to follow up on Scott's question regarding commercial EBIT margins in 2024. You expect them to increase. My understanding is that with the FDA approval of Tech 99, you indicated it would lead to an additional $20 million in depreciation and amortization. Are you still factoring that into the projected EBIT margins for 2024, or could you clarify?

No. As I mentioned, D&A effectively come when you’re commercial. So it's going to match the sales, if you will. And so we've talked about how that is a very small delivery. The way I would think about it is that model year 2024 without sales, without earnings, and without D&A tied to that specific product in 2024. If we get lucky and pull it forward, I think it will be relatively neutral to EBIT if you will. I don't think it's going to scrub your model, if we get a sliver of that in 2024. That's the way I would think about it.

Okay. So the incremental of D&A will be more of 2025 of that.

That's correct. It will ideally generate a full year of revenue, allowing for the absorption of all fixed costs. Regarding the magnitude of the depreciation and amortization, that was the figure we provided. I would factor in a full year, which includes all the benefits of a fully developed product line. Perhaps it may not be entirely complete in 2025, as we've always indicated that the full impact would be after 2025, but we will see how things develop.

Got it. Okay. And then maybe one for Rex. Rex, on the Canadian financing for Romania, usually that's a long pole in the tent right. Once the financing is kind of set. Do you guys have any sense of timing for when you might sign a contract for that project? Is it still later in the decade? Or is that kind of being pulled forward?

Yes. I don't have a lot of clarity on that one, Pete. I would say certainly later decade.

Okay. Okay, got it. All right. Thanks guys.

Yes. Thanks.

Your next question comes from the line of Bob Labick with CJS Securities. Bob, your line is open.

Thanks. Good afternoon. I wanted to ask if you could provide an update on the timeline and expectations for the Hanford Tank program. I recently read that bids have been resubmitted. How are you incorporating that into your 2024 outlook?

Certainly, Bob. I can provide some details on that. As you might be aware, we've been involved in court actions regarding this issue. The appellate court directed the matter back to the DOE for corrective action. The DOE has completed its corrective action, and we have resubmitted our original proposals. In the meantime, our competitors have raised a protest that is now with the GAO. There is quite a bit of legal activity surrounding this. Regarding the potential financial impact, we do not anticipate any transition on that contract until at least the middle of next year.

Yes. Our outlook for 2024 is similar to how we addressed 2023. We consider a range of positive and negative factors, weighing their probabilities and adjusting their timelines. We aim to be conservative in our assessments. As you know, delays in 2023 have influenced our projections, but we are still committed to meeting our guidance. We factor in all these elements into our planning. We've learned from our experiences that these processes take longer than anticipated, so we are prepared for mid-single-digit growth and have included that in our ramp-up and margin considerations.

Got it. Okay. Great. That makes a lot of sense. You discussed Moly, the FDA approval process for Tech 99, and mentioned actinium sales and non-Moly sales in medical, which are up 30%, 25%, and 30%. Could you go a little deeper into the key drivers behind that and any opportunities from the Bayer Actinium?

Yes, sure, Bob. We've got growth showing up across the board in our medical portfolio. As you know, we have diagnostic products and also therapeutic products. And so there's strong – very strong demand for germanium. We're seeing real growth there. Strontium is growing. TheraSphere continues to grow at an impressive compounded rate. Actinium 225 is showing up in our numbers a little bit because we're supporting clinical trials with our own medical device, our own generator, which produces a non-carrier added Actinium, and it's the only such generator on the market. And then we're anticipating feathering in some lutetium-177 sales for next year. So, and there are underlying things to iodine and other products that we have. And so yes, the core business is quite strong. I think it's a bit of an underappreciated asset in BWXT, and we see increasing demand in virtually every product line that we have.

Okay. That sounds super. Thanks.

You’re welcome.

Your next question comes from the line of David Strauss with Barclays. David, your line is open.

Great. Thanks. Good evening.

Hi, David.

Hey. So Rob, Q4 free cash flow working capital reversal to get to around $200 million. If you could just walk through how you get there? And then for 2024, I don't know how I should interpret the comment of improved working capital. Does that mean it's less of a drag? Or does it mean positive contributor to cash flow because I know you're seeing free cash flow growth above mid-single-digit EBITDA growth, but I would have thought with kind of flattish CapEx that we could see some pretty significant free cash flow growth next year? Thanks.

Sure. Yes. Thanks for the question, Dave. Yes. So the way that we're thinking, we always have very significant Q4. If you just look back the past couple of years, as a percentage of our free cash flow, it's always meaningful. And this year in Q4, if you just think about where we stand for the year, we're at about $40 million of year-to-date free cash flow, therefore in order to hit obviously the $200 million bogey, we've got to have $150 million plus. And the way that we're thinking about it is we're going to have a big fourth quarter in terms of profit just in general, so you start with that. And if you just think about how the cash flow statement works, right, you have net income, you have D&A, you have stock comp and JV income, that gets you almost $125 million if you just look at what we've already guided; that's sort of your starting point for operating cash flow drivers. And then you need to work higher. We always have a pretty big retainage that generally is around $25 million. You have accounts receivable, you have a SIP release. All of that gets you comfortably over $20 million of operating cash flow for the fourth quarter, and then you obviously back off CapEx. So we have a very clear path. We know the items that are coming in. And so that's how we're thinking about fourth quarter. You're right. First of all, it's pretty early to know where we stand for 2024 for free cash flow. And there's always things that wash between fourth quarter of 2023 and first quarter of 2024. So it's hard to give a growth rate when you don't know what your base is for 2023; we were using $200 million obviously just in general but whether it's 195 or 205 matters a little bit. We do see exactly what you said, which is a positive growth of working capital next year. So we're going to have the rate of the EBITDA that will kick in, that will help free cash flow to grow in line with that. Then we have the steam generator contract that we've talked about in the end that should free up some working capital and should be a positive. So we see all the trends pointing in the right direction. I'm sure you've looked in the quarter, if you look at the balance sheet, you'll see that for the third quarter cash conversion cycle go down for the first time in a couple of quarters, meaning less days. So we're starting to see real positive. That number came down by two days, and I think next year you're going to see some real positive developments there in 2024.

Okay, just to clarify, do you believe that working capital will positively contribute to cash as we reflect on the cash flow statement for 2024?

That's right. I do see the working capital items should be a positive to operating cash flow.

Okay. All right. Thanks for the clarification.

Sure.

Your final question is from Tate Sullivan from Maxim Group. Tate, your line is open.

Hi, thank you. Rex, it seems like you have a positive outlook on the fuel down blending and the government specialty materials opportunities. Is this related to an increase in volume across those various businesses? Also, could you share if higher uranium prices have any positive or negative effects on your operations? Thank you.

Yeah. Sure, Tate. Thanks for the question. Yeah. I mean, first off, we're completely uninfluenced by uranium prices, because the uranium that we process on behalf of the US government comes from stockpile and is government-furnished equipment. In fact, it's government's government-owned material all the way through. So you can think of our business as having a tolling arrangement on government material. But the reason I'm bullish on it, Tate, is because, for one thing, we're uniquely suited to do it. And I mean that in a specific sense we've got a category one in our seed license and we can handle stockpile material and no other commercial entity can do that. So we're uniquely qualified to do it. And we're bullish because it's a good business. It has a long tail on it; our competitive position is appropriate there. But then, I think there might be more to come. The NNSA, National Nuclear Security Administration has published a request for information about enrichment for national security purposes. But there will come a point when we've got to replenish the stockpile based on demand from naval nuclear propulsion and other things. And that's a special need that will require the kind of licenses and credentials and experiential qualifications that we possess. And so enrichment is a possible thing out there in the future. Certainly, there's some low-level activity in our business right now around isotope production for National Security. And if you want to think more broadly around that strategic thesis, think about whether or not we could expand into non-nuclear special materials that involve electrochemistry or chemicals or specialty metals. And so I think there's a whole world of special case materials out there that require unique processing, that require unique materials handling and accountability capabilities that we uniquely possess. And so, it's a really interesting line of business that we hope to expand in the future.

Okay. Thank you, Rex.

You're welcome.

I would now like to turn the call back over to Chase Jacobson, Vice President of Investor Relations.

Thank you everybody for joining us today. We appreciate your time and your questions and your interest in BWXT. We look forward to seeing and speaking with many of you at upcoming investor events. And if you have any further questions, you can reach out to us at investors.bwxt.com. Thank you.

Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.